Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dainippon Buys Boston Biomedical To Build On Cancer Strategy

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese pharma Dainippon will gain two clinical-stage novel drugs targeting cancer stem cells and a drug-discovery platform with the acquisition of Boston Biomedical for $200 million upfront and substantial milestones.

Advertisement

Related Content

Biopharma Quarterly Deal Statistics, Q1 2012
For Biotech VCs, Anticipation And Adjustments In The Age Of Earn-Outs
For Biotech VCs, Anticipation And Adjustments In The Age Of Earn-Outs
Deals Of The Week: GSK/Angiochem; GSK/Daiichi Sankyo; Dainippon Sumitomo/Boston Biomedical
Dainippon Sumitomo Rolls Out Latuda; Will Sepracor's $2.6 Billion Sales Force Pay Off?
Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073829

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel